首页> 外文期刊>Indian Journal of Pathology and Microbiology >Development of an efficient in vivo cell-based assay system for monitoring hepatitis C virus genotype 4a NS3/4A protease activity
【24h】

Development of an efficient in vivo cell-based assay system for monitoring hepatitis C virus genotype 4a NS3/4A protease activity

机译:开发一种用于监测丙型肝炎病毒基因型4a NS3 / 4A蛋白酶活性的基于体内细胞的高效检测系统

获取原文
           

摘要

Background: Hepatitis C virus (HCV) represents a serious worldwide healthcare problem. No protective vaccines against HCV have been developed yet due to the fact that HCV is rapidly mutable, allowing the virus to escape from the neutralizing antibodies. Understanding of HCV was initially hampered by the inability to achieve viral replication in cell culture. Given its essential roles in viral polyprotein processing and immune evasion, HCV NS3/4A protease is a prime target for antiviral chemotherapy. We aimed to establish in vivo cell-based assay system for monitoring the activity of NS3/4A protease from HCV genotype 4a, the predominant genotype in Egypt, and the Middle East. Furthermore, the developed system was used to evaluate the inhibitory potency of a series of computer-designed chemically-synthesized compounds against NS3/4A protease from HCV genotype 4a. Materials and Methods: Native as well as mutant cleavage sites to NS3/4A protease were cloned in frame into β-galactosidase gene of TA cloning vector. The target specificity of HCV NS3/4A was evaluated by coexpression of β-galactosidase containing the protease cleavage site with NS3/4A protease construct in bacterial cells. The activity of β-galactosidase was colorimetrically estimated in the cell lysate using orthonitro phenyl β-D-galactopyanoside (ONPG) as a substrate. Results and Conclusions: We successfully developed an efficient cell-based system based on the blue/white selection of bacterial cells that are able to express functionalonfunctional β-galactosidase enzyme.
机译:背景:丙型肝炎病毒(HCV)代表着严重的全球医疗保健问题。由于HCV可快速诱变,因此尚未开发出针对HCV的保护性疫苗,从而使病毒从中和抗体中逸出。最初,HCV的理解因无法在细胞培养物中实现病毒复制而受到阻碍。鉴于其在病毒多蛋白加工和免疫逃逸中的重要作用,HCV NS3 / 4A蛋白酶是抗病毒化学疗法的主要靶标。我们旨在建立基于体内细胞的检测系统,以监测来自HCV基因型4a(埃及和中东地区的主要基因型)的NS3 / 4A蛋白酶的活性。此外,已开发的系统用于评估一系列计算机设计的化学合成化合物对HCV基因型4a的NS3 / 4A蛋白酶的抑制力。材料与方法:将对NS3 / 4A蛋白酶的天然和突变切割位点按框架克隆到TA克隆载体的β-半乳糖苷酶基因中。通过在细菌细胞中共表达含有蛋白酶切割位点的β-半乳糖苷酶和NS3 / 4A蛋白酶构建体,评估HCV NS3 / 4A的靶特异性。以邻硝基苯基β-D-半乳糖苷(ONPG)为底物,通过比色法估计细胞裂解液中的β-半乳糖苷酶的活性。结果与结论:我们成功地开发出了一种基于细胞的高效系统,该系统基于能够表达功能性/非功能性β-半乳糖苷酶的细菌细胞的蓝/白选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号